nsc 106399 profile

cucurbitacin E: RN refers to (9beta,10alpha,16alpha,23E)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cucurbitacin E : A cucurbitacin in which a lanostane skeleton is multi-substituted with hydroxy, methyl and oxo substituents, with unsaturation at positions 1, 5 and 23. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	5281319
CHEBI ID	3944
SCHEMBL ID	140616
MeSH ID	M0267977

Synonym
LMST01010107
19-nor-9-beta,10-alpha-lanosta-1,5,23-triene-3,11,22-trione, 2,16-alpha,20,25-tetrahydroxy-9-methyl-, 25-acetate
alpha-elaterine
einecs 242-325-2
brn 2343323
25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-19-norlanosta-1,5,23-triene-3,11,22-trione (9beta,10alpha,16alpha,23e)-
nsc 106399
19-nor-9beta,10alpha-lanosta-1,5,23-triene-3,11,22-trione, 2,16alpha,20,25-tetrahydroxy-9-methyl-, 25-acetate
alpha-elaterin
19-norlanosta-1,5,23-triene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (9beta,10alpha,16alpha,23e)-
2,16alpha,20,25-tetrahydroxy-9beta-methyl-10alpha,-19-norlanosta-1,5,23(e)-triene-3,11,22-trione 25-acetate
cucurbitacine-e
CUE ,
.alpha.-elaterin
18444-66-1
19-nor-9.beta.,5,23-triene-3,11,22-trione, 2,16.alpha.,20,25-tetrahydroxy-9-methyl-, 25-acetate
cucurbitacin e
19-norlanosta-1,23-triene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (9.beta.,10.alpha.,16.alpha.,23e)-
nsc106399 ,
.alpha.-elaterine
elaterin, alpha
cucurbitacine e
nsc-106399
nsc521775
nsc-521775
C08797
chebi:3944 ,
(23e)-25-acetyloxy-2,16alpha,20-trihydroxy-9beta-methyl-19-nor-10alpha-lanosta-1,5,23-triene-3,11,22-trione
(4r,23e)-2,16alpha,20-trihydroxy-9beta,10,14-trimethyl-1,11,22-trioxo-4,9-cyclo-9,10-secocholesta-2,5,23-trien-25-yl acetate
2,16alpha,20,25-tetrahydroxy-9-methyl-19-nor-9beta,10alpha-lanosta-1,5,23-triene-3,11,22-trione 25-acetate
[(e,6r)-6-[(8s,9r,10r,13r,14s,16r,17r)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-8,10,12,15,16,17-hexahydro-7h-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl] acetate
unii-v8a45xyi21
v8a45xyi21 ,
AKOS015896851
cucurbitacin e [mi]
(-)-cucurbitacin e
(9.beta.,10.alpha.,16.alpha.,23e)-25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-19-norlanosta-1,5,23-triene-3,11,22-trione
19-norlanosta-1,5,23-triene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (9.beta.,10.alpha.,16.alpha.,23e)-
SCHEMBL140616
CS-3817
19-norlanosta-1,5,23-triene-3,11,22-trione,25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (9b,10a,16a,23e)-
AC-34285
cucurbitacin-e
HY-N0417
mfcd00135936
cucurbitacin e (alpha-elaterin)
Q5192451
A930353
-elaterin;-elaterine
AS-76174
DTXSID601030496

Excerpt	Reference	Relevance
") decreased warfarin clearance (28-32%), increased the area under the curve (AUC0-∞; 55-62%) and prolonged plasma half-life (t1/2; 58-72%)."	( Effects of cucurbitacin e, a tetracyclic triterpene compound from Cucurbitaceae, on the pharmacokinetics and pharmacodynamics of warfarin in rats. Chen, A; Ding, T; Liu, M; Tang, Y; Wang, X; Zhang, Y, 2015)	0.42

Excerpt	Reference	Relevance
"The aim of this investigation was to comprehensively assess CuE related hepatotoxicity and potential drug-drug interactions involving CYP3A and P-glycoprotein (P-gp)."	( Comprehensive assessment of Cucurbitacin E related hepatotoxicity and drug-drug interactions involving CYP3A and P-glycoprotein. Liu, M; Lu, J; Sun, M; Wang, X; Zhang, Y, 2017)	0.46
" Therefore, CuE as a dual functional regulator of both CYP3A and P-gp may cause complex drug-drug interactions."	( Comprehensive assessment of Cucurbitacin E related hepatotoxicity and drug-drug interactions involving CYP3A and P-glycoprotein. Liu, M; Lu, J; Sun, M; Wang, X; Zhang, Y, 2017)	0.46

Excerpt	Relevance	Reference
" Both effects increased in proportion to the dosage of CuE and apoptosis was induced via mitochondria- and caspase-dependent pathways."	( Cucurbitacin E as inducer of cell death and apoptosis in human oral squamous cell carcinoma cell line SAS. Chang, CC; Hsu, YC; Hung, CM; Ko, SY; Lin, CW, 2013)	0.39

Class	Description
cucurbitacin	Any one of a class of tetracyclic triterpenoids, formally derived from the triterpene hydrocarbon cucurbitane, developed by some plants (especially those of the family Cucurbitaceaeas) as a defence mechanism against herbivores.
tertiary alpha-hydroxy ketone	An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Integrin alpha-L	Homo sapiens (human)	IC50 (µMol)	0.1800	0.0008	0.6020	3.7800	AID337982
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell	Integrin alpha-L	Homo sapiens (human)
phagocytosis	Integrin alpha-L	Homo sapiens (human)
inflammatory response	Integrin alpha-L	Homo sapiens (human)
cell adhesion	Integrin alpha-L	Homo sapiens (human)
heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules	Integrin alpha-L	Homo sapiens (human)
leukocyte cell-cell adhesion	Integrin alpha-L	Homo sapiens (human)
cell-matrix adhesion	Integrin alpha-L	Homo sapiens (human)
signal transduction	Integrin alpha-L	Homo sapiens (human)
integrin-mediated signaling pathway	Integrin alpha-L	Homo sapiens (human)
memory T cell extravasation	Integrin alpha-L	Homo sapiens (human)
receptor clustering	Integrin alpha-L	Homo sapiens (human)
cell-cell adhesion	Integrin alpha-L	Homo sapiens (human)
cell adhesion mediated by integrin	Integrin alpha-L	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Integrin alpha-L	Homo sapiens (human)
ICAM-3 receptor activity	Integrin alpha-L	Homo sapiens (human)
metal ion binding	Integrin alpha-L	Homo sapiens (human)
cell adhesion molecule binding	Integrin alpha-L	Homo sapiens (human)
integrin binding	Integrin alpha-L	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Integrin alpha-L	Homo sapiens (human)
cell surface	Integrin alpha-L	Homo sapiens (human)
membrane	Integrin alpha-L	Homo sapiens (human)
integrin alphaL-beta2 complex	Integrin alpha-L	Homo sapiens (human)
specific granule membrane	Integrin alpha-L	Homo sapiens (human)
extracellular exosome	Integrin alpha-L	Homo sapiens (human)
integrin complex	Integrin alpha-L	Homo sapiens (human)
external side of plasma membrane	Integrin alpha-L	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (107)

Assay ID	Title	Year	Journal	Article
AID337913	Growth inhibition of human A549 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337965	Growth inhibition of human BT549 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337915	Growth inhibition of human HOP62 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337922	Growth inhibition of human COLO205 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337988	Cytotoxicity against human JY cells after 48 hrs by MTT assay	1994	Journal of natural products, Nov, Volume: 57, Issue:11	Cucurbitacins, cell adhesion inhibitors from Conobea scoparioides.
AID337914	Growth inhibition of human EKVX cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID592722	Antiproliferative activity against serum-stimulated rat HSC-T6 cells after 24 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines.
AID337938	Growth inhibition of human SK-MEL-2 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337939	Growth inhibition of human SK-MEL-28 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337926	Growth inhibition of human HT-29 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID592728	Antioxidant activity in rat liver microsomes assessed as inhibition of lipid peroxidation after 30 mins	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines.
AID337931	Growth inhibition of human SF539 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337917	Growth inhibition of human NCI-H226 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337942	Growth inhibition of human UACC62 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337955	Growth inhibition of human TK10 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337959	Growth inhibition of human MCF7 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID592718	Ratio of IC50 to EC50 for hepatoprotective activity in human HepG2 cells	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines.
AID337964	Growth inhibition of human MDA-N cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID1225627	Inhibition of HSP90 in human MCF7 cells assessed as induction of heat shock response-mediated HSP27 production at 0.5 times to 5 times IC50 after 24 hrs by Western blot analysis	2015	Journal of natural products, Apr-24, Volume: 78, Issue:4	Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID337916	Growth inhibition of human HOP92 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337944	Growth inhibition of human OVCAR-3 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337984	Cytotoxicity against human JY cells assessed as inhibition of thymidine uptake at 1 uM by scintillation counting	1994	Journal of natural products, Nov, Volume: 57, Issue:11	Cucurbitacins, cell adhesion inhibitors from Conobea scoparioides.
AID337929	Growth inhibition of human SF268 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337920	Growth inhibition of human NCI-H460 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337907	Growth inhibition of human CCRF-CEM cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337941	Growth inhibition of human UACC257 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337954	Growth inhibition of human SN12C cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337956	Growth inhibition of human UO31 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337966	Growth inhibition of human T47D cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337924	Growth inhibition of human HCT116 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337992	Inhibition of actin polymerization in fMLP-stimulated human neutrophils assessed as positive fluorescence signal at 3.3 uM	1994	Journal of natural products, Nov, Volume: 57, Issue:11	Cucurbitacins, cell adhesion inhibitors from Conobea scoparioides.
AID479445	Inhibition of STAT3 phosphorylation in human U937 cells at 10 uM after 24 hrs by Western blotting	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells.
AID337943	Growth inhibition of human IGROV1 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337912	Growth inhibition of human SR cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337949	Growth inhibition of human 786-0 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337910	Growth inhibition of human MOLT4 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337930	Growth inhibition of human SF295 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID1225624	Inhibition of HSP90 in human MCF7 cells assessed as Raf degradation at 0.5 times to 5 times IC50 after 24 hrs by Western blot analysis	2015	Journal of natural products, Apr-24, Volume: 78, Issue:4	Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID337948	Growth inhibition of human SKOV3 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID479446	Inhibition of STAT3 phosphorylation in human U937 cells at 100 uM after 24 hrs by Western blotting	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells.
AID337983	Cytotoxicity against human JY cells assessed as inhibition of thymidine uptake at 0.3 uM by scintillation counting	1994	Journal of natural products, Nov, Volume: 57, Issue:11	Cucurbitacins, cell adhesion inhibitors from Conobea scoparioides.
AID337935	Growth inhibition of human LOXIMVI cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID354490	Growth inhibition of human lung cancer cells	2004	Journal of natural products, Aug, Volume: 67, Issue:8	An analysis of cytotoxic botanical formulations used in the traditional medicine of ancient Persia as abortifacients.
AID354488	Growth inhibition of human colon cancer cells	2004	Journal of natural products, Aug, Volume: 67, Issue:8	An analysis of cytotoxic botanical formulations used in the traditional medicine of ancient Persia as abortifacients.
AID354491	Growth inhibition of human CNS cancer cells	2004	Journal of natural products, Aug, Volume: 67, Issue:8	An analysis of cytotoxic botanical formulations used in the traditional medicine of ancient Persia as abortifacients.
AID337933	Growth inhibition of human SNB75 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337946	Growth inhibition of human OVCAR5 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337987	Cytotoxicity against human JY cells assessed as inhibition of thymidine uptake up to 5 hrs	1994	Journal of natural products, Nov, Volume: 57, Issue:11	Cucurbitacins, cell adhesion inhibitors from Conobea scoparioides.
AID337927	Growth inhibition of human KM12 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337925	Growth inhibition of human HCT15 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID592714	Cytotoxicity against human HepG2 cells after 24 hrs assessed as inhibition of cell viability by MTT assay	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines.
AID479440	Cytotoxicity against human HL60 cells after 72 hrs by WST-8 assay	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells.
AID337932	Growth inhibition of human SNB19 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID479444	Cell cycle arrest in human U937 cells assessed as increase of cell population at G2/M phase at 100 nM after 24 hrs using propidium iodide staining by flow cytometry relative to control	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells.
AID337950	Growth inhibition of human A498 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337952	Growth inhibition of human Caki1 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337908	Growth inhibition of human HL-60(TB) cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337947	Growth inhibition of human OVCAR8 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337909	Growth inhibition of human K562 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337945	Growth inhibition of human OVCAR4 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID479441	Cytotoxicity against human HT1080 cells after 72 hrs by WST-8 assay	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells.
AID1225622	Inhibition of HSP90 in human MCF7 cells assessed as Her2 degradation at 0.5 times to 5 times IC50 after 24 hrs by Western blot analysis	2015	Journal of natural products, Apr-24, Volume: 78, Issue:4	Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID479448	Inhibition of LIMK1/2 phosphorylation in human U937 cells at 0.1 to 100 nM after 24 hrs by Western blotting	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells.
AID337963	Growth inhibition of human MDA-MB-435 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337957	Growth inhibition of human PC3 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID479442	Cell cycle arrest in human U937 cells assessed as reduction of cell population at G0/G1 phase at 100 nM after 24 hrs using propidium iodide staining by flow cytometry relative to control	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells.
AID337921	Growth inhibition of human NCI-H522 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID592719	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines.
AID337995	Inhibition of PKC in human JY cells	1994	Journal of natural products, Nov, Volume: 57, Issue:11	Cucurbitacins, cell adhesion inhibitors from Conobea scoparioides.
AID337934	Growth inhibition of human U251 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337960	Growth inhibition of human NCI/ADR-RES cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337982	Inhibition of LFA1 expressed in human JY cells interaction with ICAM1-IG expressed in human HeLa cell monolayer after 45 mins by cell adhesion assay	1994	Journal of natural products, Nov, Volume: 57, Issue:11	Cucurbitacins, cell adhesion inhibitors from Conobea scoparioides.
AID337928	Growth inhibition of human SW620 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337962	Growth inhibition of human Hs 578T cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID592720	Ratio of IC50 for human HepG2 cells to IC50 for human HeLa cells	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines.
AID592715	Hepatoprotective activity in human HepG2 cells assessed as inhibition of CCl4-induced toxicity after 24 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines.
AID337940	Growth inhibition of human SK-MEL-5 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337936	Growth inhibition of human MALME-3M cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337911	Growth inhibition of human RPMI8266 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337958	Growth inhibition of human DU145 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337991	Inhibition of actin polymerization in fMLP-stimulated human neutrophils assessed as positive fluorescence signal at 1 uM	1994	Journal of natural products, Nov, Volume: 57, Issue:11	Cucurbitacins, cell adhesion inhibitors from Conobea scoparioides.
AID337989	Cytotoxicity against human JY cells up to 45 mins	1994	Journal of natural products, Nov, Volume: 57, Issue:11	Cucurbitacins, cell adhesion inhibitors from Conobea scoparioides.
AID1386642	Inhibition of AChE (unknown origin) at 10 uM using acetylthiocholine iodide as substrate preincubated for 10 mins followed by substrate addition measured after 10 mins by Ellman's method	2018	Journal of natural products, 09-28, Volume: 81, Issue:9	Colocynthenins A-D, Ring-A seco-Cucurbitane Triterpenoids from the Fruits of Citrullus colocynthis.
AID337951	Growth inhibition of human ACHN cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID479449	Decrease of F to G actin ratio in human HT1080 cells at 100 nM after 24 hrs	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells.
AID479272	Cytotoxicity against human U937 cells after 72 hrs by WST-8 assay	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells.
AID354494	Growth inhibition of human prostate cancer cells	2004	Journal of natural products, Aug, Volume: 67, Issue:8	An analysis of cytotoxic botanical formulations used in the traditional medicine of ancient Persia as abortifacients.
AID337919	Growth inhibition of human NCI-H322M cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337993	Inhibition of actin polymerization in fMLP-stimulated human neutrophils assessed as positive fluorescence signal at 0.33 uM	1994	Journal of natural products, Nov, Volume: 57, Issue:11	Cucurbitacins, cell adhesion inhibitors from Conobea scoparioides.
AID479447	Inhibition of cofilin phosphorylation in human U937 cells after 24 hrs by Western blotting	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells.
AID337923	Growth inhibition of human HCC2998 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID1225621	Inhibition of HSP90 in human MCF7 cells assessed as pAkt degradation at 0.5 times to 5 times IC50 after 24 hrs by Western blot analysis	2015	Journal of natural products, Apr-24, Volume: 78, Issue:4	Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID1225626	Inhibition of HSP90 in human MCF7 cells assessed as induction of heat shock response-mediated HSP70 production at 0.5 times to 5 times IC50 after 24 hrs by Western blot analysis	2015	Journal of natural products, Apr-24, Volume: 78, Issue:4	Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID479443	Cell cycle arrest in human U937 cells assessed as reduction of cell population at S phase at 100 nM after 24 hrs using propidium iodide staining by flow cytometry relative to control	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells.
AID337961	Growth inhibition of human MDA-MB-231 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID592721	Cytotoxicity against rat HSC-T6 cell after 24 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines.
AID337953	Growth inhibition of human RXF393 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337918	Growth inhibition of human NCI-H23 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID337994	Effect on cell activation in human JY cells assessed as inhibition of Ca2+ flux	1994	Journal of natural products, Nov, Volume: 57, Issue:11	Cucurbitacins, cell adhesion inhibitors from Conobea scoparioides.
AID337937	Growth inhibition of human M14 cells	1994	Journal of natural products, Oct, Volume: 57, Issue:10	Cucurbitacins: differential cytotoxicity, dereplication and first isolation from Gonystylus keithii.
AID592724	Hepatoprotective activity in human HepG2 cells assessed as protection against cell damage after 24 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines.
AID592723	Ratio of IC50 to EC50 for antiproliferative activity in rat HSC-T6 cells	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines.
AID1225623	Inhibition of HSP90 in human MCF7 cells assessed as Cdk6 degradation at 0.5 times to 5 times IC50 after 24 hrs by Western blot analysis	2015	Journal of natural products, Apr-24, Volume: 78, Issue:4	Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID1225605	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay	2015	Journal of natural products, Apr-24, Volume: 78, Issue:4	Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID1225625	Inhibition of HSP90 in human MCF7 cells assessed as induction of heat shock response-mediated HSP90 production at 0.5 times to 5 times IC50 after 24 hrs by Western blot analysis	2015	Journal of natural products, Apr-24, Volume: 78, Issue:4	Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
AID337985	Cytotoxicity against human JY cells assessed as inhibition of thymidine uptake at 3.3 uM by scintillation counting	1994	Journal of natural products, Nov, Volume: 57, Issue:11	Cucurbitacins, cell adhesion inhibitors from Conobea scoparioides.
AID354489	Growth inhibition of human breast cancer cells	2004	Journal of natural products, Aug, Volume: 67, Issue:8	An analysis of cytotoxic botanical formulations used in the traditional medicine of ancient Persia as abortifacients.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	2 (2.44)	18.7374
1990's	4 (4.88)	18.2507
2000's	13 (15.85)	29.6817
2010's	46 (56.10)	24.3611
2020's	17 (20.73)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (2.44%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	80 (97.56%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.13	1	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
phenylbutazone Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.	2.06	1	pyrazolidines	antirheumatic drug; EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor; metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
sevoflurane Sevoflurane: A non-explosive inhalation anesthetic used in the induction and maintenance of general anesthesia. It does not cause respiratory irritation and may also prevent PLATELET AGGREGATION.. sevoflurane : An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups.	2.41	1	ether; organofluorine compound	central nervous system depressant; inhalation anaesthetic; platelet aggregation inhibitor
carbon tetrachloride Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.	2.06	1	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
adenosine diphosphate Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.	2.13	1	adenosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	fundamental metabolite; human metabolite
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.49	2	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
ecdysone [no description available]	2.31	1	14alpha-hydroxy steroid; 22-hydroxy steroid; 25-hydroxy steroid; 2beta-hydroxy steroid; 3beta-sterol; 6-oxo steroid; ecdysteroid	prohormone
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.21	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
ng-nitroarginine methyl ester NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.	2.06	1	alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid [no description available]	2.06	1	chromanol; monocarboxylic acid; phenols	antioxidant; ferroptosis inhibitor; neuroprotective agent; radical scavenger; Wnt signalling inhibitor
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.81	3	D-glucopyranose	epitope; mouse metabolite
lissamine rhodamine b lissamine rhodamine B: RN given refers to parent cpd; Lissamine Rhodamine B refers to Na salt	2.08	1
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	2.41	1	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
beta-peltatin beta-peltatin : An organic heterotetracyclic compound that is alpha-peltatin in which the phenolic hydroxy group of the 4-hydroxy-3,5-dimethoxyphenyl substitutent had been converted into the corresponding methyl ether.	3.12	1	furonaphthodioxole; gamma-lactone; lignan; organic heterotetracyclic compound; phenols	antineoplastic agent; plant metabolite
phosphites Phosphites: Inorganic salts or organic esters of phosphorous acid that contain the (3-)PO3 radical. (From Grant & Hackh's Chemical Dictionary, 5th ed). phosphite(3-) : A trivalent inorganic anion obtained by removal of all three protons from phosphorous acid.	2.15	1	phosphite ion; trivalent inorganic anion
cucurbitacins [no description available]	3.33	6	11-oxo steroid
celastrol [no description available]	2.11	1	monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite
hydroxyl radical Hydroxyl Radical: The univalent radical OH. Hydroxyl radical is a potent oxidizing agent.	2.03	1	oxygen hydride; oxygen radical; reactive oxygen species
singlet oxygen Singlet Oxygen: An excited state of molecular oxygen generated photochemically or chemically. Singlet oxygen reacts with a variety of biological molecules such as NUCLEIC ACIDS; PROTEINS; and LIPIDS; causing oxidative damages.	2.03	1	chalcogen; monoatomic oxygen; nonmetal atom	macronutrient
cucurbitacin r cucurbitacin R: from Cayaponia tayuya roots; structure in first source. 23,24-dihydrocucurbitacin D : A 23,24-dihydrocucurbitacin in which a lanostane skeleton is multi-substituted with hydroxy, methyl and oxo substituents, with unsaturation at position 5.	1.98	1	23,24-dihydrocucurbitacin; secondary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone
sorafenib [no description available]	2.6	1	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
23,24-dihydrocucurbitacin b 23,24-dihydrocucurbitacin B: from the leaves of Morierina montana Vieill; structure in first source. 23,24-dihydrocucurbitacin B : A 23,24-dihydrocucurbitacin in which a lanostane skeleton is multi-substituted with hydroxy, methyl and oxo substituents, with unsaturation at position 5; a hydroxy function at C-25 is acetylated.	2.77	3	23,24-dihydrocucurbitacin; secondary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone
anthricin anthricin: antitumor constituent from Anthriscus sylvestris (L.) Hoffm; structure in first source. deoxypodophyllotoxin : A member of the class of furonaphthodioxoles that is (5R,5aR,8aR)-5,8,8a,9-tetrahydro-2H-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5aH)-one substituted at position 5 by a 3,4,5-trimethoxyphenyl group.	3.12	1	furonaphthodioxole; gamma-lactone; lignan; methoxybenzenes	antineoplastic agent; apoptosis inducer; plant metabolite
phalloidine Phalloidine: Very toxic polypeptide isolated mainly from AMANITA phalloides (Agaricaceae) or death cup; causes fatal liver, kidney and CNS damage in mushroom poisoning; used in the study of liver damage.. phalloidin : A homodetic bicyclic heptapeptide having a sulfide bridge.	1.99	1	homodetic cyclic peptide
gingerol gingerol: an active ingredient in GINGER along with SHOGAOL. a nonvolatile methoxy phenyl decanone. gingerol : A beta-hydroxy ketone that is 5-hydroxydecan-3-one substituted by a 4-hydroxy-3-methoxyphenyl moiety at position 1; believed to inhibit adipogenesis. It is a constituent of fresh ginger.	2.04	1	beta-hydroxy ketone; guaiacols	antineoplastic agent; plant metabolite
ferulic acid ferulate : A monocarboxylic acid anion obtained by the deprotonation of the carboxy group of ferulic acid.	2.04	1	ferulic acids	anti-inflammatory agent; antioxidant; apoptosis inhibitor; cardioprotective agent; MALDI matrix material; plant metabolite
glycosides [no description available]	2.04	1
huperzine a [no description available]	2.17	1	organic heterotricyclic compound; primary amino compound; pyridone; sesquiterpene alkaloid	EC 3.1.1.7 (acetylcholinesterase) inhibitor; neuroprotective agent; nootropic agent; plant metabolite
capsaicin ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.	2.04	1	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
D-fructopyranose [no description available]	2.01	1	cyclic hemiketal; D-fructose; fructopyranose	sweetening agent
thioacetamide Thioacetamide: A crystalline compound used as a laboratory reagent in place of HYDROGEN SULFIDE. It is a potent hepatocarcinogen.. thioacetamide : A thiocarboxamide consiting of acetamide having the oxygen replaced by sulfur.	2.13	1	thiocarboxamide	hepatotoxic agent
silybin [no description available]	2.06	1
quercetin [no description available]	2.06	1	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
bilirubin [no description available]	2.03	1	biladienes; dicarboxylic acid	antioxidant; human metabolite; mouse metabolite
linoleic acid Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed). linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry.	2.03	1	octadecadienoic acid; omega-6 fatty acid	algal metabolite; Daphnia galeata metabolite; plant metabolite
cucurbitacin b [no description available]	3.95	12	cucurbitacin; secondary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone
cucurbitacin d cucurbitacin D: toxic constituent in edible gourd; see also records for cucurbitacins & specific cucurbitacins. cucurbitacin D : A cucurbitacin in which a lanostane skeleton is multi-substituted with hydroxy, methyl and oxo substituents, with unsaturation at positions 5 and 23.	4.38	6	cucurbitacin; secondary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone
cucurbitacin i cucurbitacin I: toxic constituent in edible gourd; see also records for cucurbitacins & specific cucurbitacins. cucurbitacin I : A cucurbitacin that is 9,10,14-trimethyl-4,9-cyclo-9,10-secocholesta-2,5,23-triene substituted by hydroxy groups at positions 2, 16, 20 and 25 and oxo groups at positions 1, 11 and 22.	4.94	11	cucurbitacin; tertiary alpha-hydroxy ketone	antineoplastic agent; plant metabolite
myricetin [no description available]	2.6	1	7-hydroxyflavonol; hexahydroxyflavone	antineoplastic agent; antioxidant; cyclooxygenase 1 inhibitor; food component; geroprotector; hypoglycemic agent; plant metabolite
geldanamycin [no description available]	2.11	1	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound	antimicrobial agent; antineoplastic agent; antiviral agent; cysteine protease inhibitor; Hsp90 inhibitor
cytochalasin b Cytochalasin B: A cytotoxic member of the CYTOCHALASINS.. cytochalasin B : An organic heterotricyclic compound, that is a mycotoxin which is cell permeable an an inhibitor of cytoplasmic division by blocking the formation of contractile microfilaments.	1.98	1	cytochalasin; lactam; lactone; organic heterotricyclic compound	actin polymerisation inhibitor; metabolite; mycotoxin; platelet aggregation inhibitor
bafilomycin a1 bafilomycin A1: from Streptomyces griseus; structure given in first source. bafilomycin A1 : The most used of the bafilomycins, a family of toxic macrolide antibiotics derived from Streptomyces griseus.	2.13	1	cyclic hemiketal; macrolide antibiotic; oxanes	apoptosis inducer; autophagy inhibitor; bacterial metabolite; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; ferroptosis inhibitor; fungicide; potassium ionophore; toxin
cucurbitacin I 2-O-beta-D-glucopyranoside cucurbitacin I 2-O-beta-D-glucopyranoside : A triterpenoid saponin that is cucurbitacin I attached to a beta-D-glucopyranosyl residue at position 2 via a glycosidic linkage. It has been isolated from Machilus yaoshansis.	2.06	1	beta-D-glucoside; cucurbitacin; monosaccharide derivative; tertiary alpha-hydroxy ketone; triterpenoid saponin	plant metabolite
verlukast verlukast: LTD4 receptor antagonist	2.05	1
jasplakinolide jasplakinolide: cyclodepsipeptide isolated from marine sponge Jaspis; active against Candida; RN refers to 2S-(2R,4E,6S,8R*)-isomer; structure in first source. jaspamide : A cyclodepsipeptide isolated from Jaspis splendens and has been shown to exhibit antineoplastic activity. It is an actin polymerization and stabilization inducer.	2.07	1	cyclodepsipeptide; phenols	actin polymerisation inducer; animal metabolite; antifungal agent; antineoplastic agent; apoptosis inducer; marine metabolite; neuroprotective agent
cucurbitacin iib cucurbitacin IIb: has anti-inflammatory activity; isolated from Hemsleya amabilis; structure in first source	2.03	1
gedunin [no description available]	2.11	1	acetate ester; enone; epoxide; furans; lactone; limonoid; organic heteropentacyclic compound; pentacyclic triterpenoid	antimalarial; antineoplastic agent; Hsp90 inhibitor; plant metabolite
eosine i bluish Eosine I Bluish: A red fluorescein dye used as a histologic stain. It may be cytotoxic, mutagenic, and inhibit certain mitochondrial functions.	2.41	2	organic sodium salt	fluorescent dye; histological dye
endothelin-1 Endothelin-1: A 21-amino acid peptide produced in a variety of tissues including endothelial and vascular smooth-muscle cells, neurons and astrocytes in the central nervous system, and endometrial cells. It acts as a modulator of vasomotor tone, cell proliferation, and hormone production. (N Eng J Med 1995;333(6):356-63)	2.6	1
chitosan [no description available]	2.15	1
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	2.06	1	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.11	1	benzenes; hydroxycoumarin; methyl ketone
epidermal growth factor Epidermal Growth Factor: A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form.	2.6	1
lipoteichoic acid lipoteichoic acid: lipopolysaccharides with an acyl group anchored to the cell membrane of gram-positive bacteria; functions as an adhesion molecule to facilitate the binding of bacteria to cells, colonization, and invasion; interacts with CD14 to induce NF-κB activation and inflammatory cytokine production; can function as surface antigen; inhibits remineraliztion of artificial lesions and surface-softened enamels;. lipoteichoic acid : A teichoic acid which is covalently bound to a lipid.	2.11	1
concanavalin a Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.	2.41	1

Condition	Relationship Strength	Studies
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.93	1
Cirrhosis [description not available]	2.06	1
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	2.06	1
Benign Neoplasms [description not available]	2.51	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.51	2
Cancer of Colon [description not available]	2.41	1
Colorectal Cancer [description not available]	2.58	2
Colonic Neoplasms Tumors or cancer of the COLON.	2.41	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.58	2
Hepatitis INFLAMMATION of the LIVER.	2.41	1
Airway Remodeling The structural changes in the number, mass, size and/or composition of the airway tissues.	2.41	1
Innate Inflammatory Response [description not available]	3.44	6
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	3.44	6
Cognitive Decline [description not available]	2.41	1
Cognitive Dysfunction Diminished or impaired mental and/or intellectual function.	2.41	1
Benedict Syndrome [description not available]	2.6	1
Clinically Isolated CNS Demyelinating Syndrome [description not available]	2.6	1
Demyelinating Diseases Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.	2.6	1
Carcinoma, Non-Small Cell Lung [description not available]	2.98	3
Cancer of Lung [description not available]	3.08	4
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.98	3
Lung Neoplasms Tumors or cancer of the LUNG.	3.08	4
Hepatocellular Carcinoma [description not available]	2.88	3
Cancer of Liver [description not available]	2.88	3
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.88	3
Liver Neoplasms Tumors or cancer of the LIVER.	2.88	3
Astrocytoma, Grade IV [description not available]	2.72	2
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.72	2
Osteoarthritis of Knee [description not available]	2.6	1
Osteoarthritis, Knee Noninflammatory degenerative disease of the knee joint consisting of three large categories: conditions that block normal synchronous movement, conditions that produce abnormal pathways of motion, and conditions that cause stress concentration resulting in changes to articular cartilage. (Crenshaw, Campbell's Operative Orthopaedics, 8th ed, p2019)	2.6	1
Asthma, Bronchial [description not available]	2.21	1
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	2.21	1
Metastase [description not available]	2.25	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.25	1
Esophageal Squamous Cell Carcinoma A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.	2.25	1
Cancer of Esophagus [description not available]	2.25	1
Invasiveness, Neoplasm [description not available]	2.53	2
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	2.25	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.15	1
Cardiometabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.	2.15	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.54	2
Insulin Sensitivity [description not available]	2.15	1
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	2.15	1
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	2.15	1
Metabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.	2.15	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.15	1
Graft-Versus-Host Disease [description not available]	2.17	1
Acute Disease Disease having a short and relatively severe course.	2.17	1
Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.	2.17	1
Benign Neoplasms, Brain [description not available]	2.85	3
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.85	3
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	2.54	2
Leucocythaemia [description not available]	2.51	2
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	2.51	2
Carcinoma, Epidermoid [description not available]	2.08	1
Cancer of Mouth [description not available]	2.08	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.08	1
Mouth Neoplasms Tumors or cancer of the MOUTH.	2.08	1
Breast Cancer [description not available]	2.08	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.08	1
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2.1	1
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	2.1	1
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	2.1	1
Nasopharyngeal Carcinoma A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.	2.1	1
Carcinoma, Anaplastic [description not available]	2.1	1
Cancer of Nasopharynx [description not available]	2.1	1
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	2.1	1
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	2.1	1
Idiopathic Parkinson Disease [description not available]	2.1	1
Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)	2.1	1
Allergic Encephalomyelitis [description not available]	2.13	1
Cirrhosis, Liver [description not available]	2.13	1
Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.	2.13	1
Acute Liver Injury, Drug-Induced [description not available]	2.15	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	2.15	1
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	2.05	1
Cancer of Ovary [description not available]	2.74	3
Sarcoma, Epithelioid [description not available]	2.45	2
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	2.74	3
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	2.45	2
Cancer of Pancreas [description not available]	2.05	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.05	1
Experimental Neoplasms [description not available]	2.05	1
Angiogenesis, Pathologic [description not available]	2.05	1
Anasarca [description not available]	2.06	1
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	2.06	1
Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.	2.46	2
Animal Mammary Carcinoma [description not available]	2.07	1
Bilirubinemia [description not available]	2.03	1
Cancer of Prostate [description not available]	1.99	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	1.99	1

nsc 106399

Description

Cross-References

Synonyms (51)

Research Excerpts

Pharmacokinetics

Compound-Compound Interactions

Dosage Studied

Drug Classes (2)

Protein Targets (1)

Inhibition Measurements

Biological Processes (13)

Molecular Functions (5)

Ceullar Components (8)

Bioassays (107)

Research

Studies (82)

Study Types

nsc 106399

Description

Cross-References

Synonyms (51)

Research Excerpts

Pharmacokinetics

Compound-Compound Interactions

Dosage Studied

Drug Classes (2)

Protein Targets (1)

Inhibition Measurements

Biological Processes (13)

Molecular Functions (5)

Ceullar Components (8)

Bioassays (107)

Research

Studies (82)

Study Types

Related Drugs (55)

Related Conditions (91)